Searchable abstracts of presentations at key conferences in endocrinology

ea0092op-09-03 | Oral Session 9: Thyroid Eye Disease | ETA2023

Linsitinib, AN IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease

Gulbins Anne , Horstmann Mareike , Daser Anke , Flogel Ulrich , Oeverhaus Michael , Bechrakis Nikolaos , Paul Banga J , Keitsch Simone , Wilker Barbara , Krause Gerd , Hammer Gary , Spencer Andy , Zeidan Ryan , Eckstein Anja , Philipp Svenja , Gortz Gina-Eva

Study objective: We investigated the effect of linsitinib, a dual small-molecule kinase inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the Insulin receptor (IR), on Graves’ Disease and thyroid eye disease. Graves‘ disease (GD), also known as ‘Basedow’s disease‘, is the most common cause for hyperthyroidism, typically presenting in patients between 40-60 years. GD is an autoimmune condition of the thyroid which is caused by autoanti...